World's largest Covid-19 vaccine rollout in India begins today

New Delhi - Over the coming months, India aims to inoculate around 300 million people.

India begins one of the world’s biggest coronavirus vaccination programmes on Saturday, hoping to end a pandemic that has killed 150,000 people in the country and torpedoed the economy.

The country is home to the world’s largest vaccine makers and has one of the biggest immunization programs. But there is no playbook for the enormity of the challenge.

The first dose of a vaccine was administered to a health worker at All Indian Institute of Medical Sciences in the capital New Delhi, after Prime Minister Narendra Modi kickstarted the campaign with a nationally televised speech. Priority groups across the vast country, from the Himalayan mountains to the Andaman Islands in the Bay of Bengal, began receiving it shortly after.

“We are launching the world’s biggest vaccination drive and it shows the world our capability,” Modi said in his address. He implored citizens to keep their guard up and not to believe any “rumors about the safety of the vaccines.”

It was not clear if Modi, 70, has taken the vaccine himself like other world leaders as an example of the shot’s safety. His government has said politicians will not be considered priority groups in the first phase of the rollout.

Health officials haven’t specified what percentage of the nearly 1.4 billion people will be targeted by the campaign. But experts say it will almost certainly be the largest such drive globally.

AFP looks at the numbers involved in the vast and complex undertaking compounded by weak infrastructure, online hoaxes and security and safety worries:

Over the coming months, India aims to inoculate around a quarter of the population, or 300 million people. They include healthcare workers, people aged over 50 and those at high risk.

On the first day, around 300,000 people will be vaccinated at 3,000 centres. About 150,000 staff in 700 districts have been trained to administer jabs and keep records. Around 100 people will be vaccinated in each of the 3,006 centers across the country on the first day, the Health Ministry said this week.

The government aims to manage the entire process digitally with its own app, CoWIN, which will link every vaccine dose to its recipient.

India has four “mega depots” to take delivery of the vaccines and transport them to state distribution hubs in temperature-controlled vans, keeping the doses colder than 8 degrees Celsius.

A total of 29,000 cold-chain points, 240 walk-in coolers, 70 walk-in freezers, 45,000 ice-lined refrigerators, 41,000 deep freezers and 300 solar fridges are at the ready.

These will be needed once the Indian summer arrives in the coming months.

In one recent practice run in a rural area, a consignment of dummy vaccines was photographed being delivered by bicycle.

To stop any of the vials being stolen and being sold on India’s large drugs black market, authorities are taking no chances, with armed police guarding every truck.

CCTVs are in place at warehouses with entry subject to fingerprint authentication. Automated data loggers will monitor storage temperature and transfer messages every three seconds to a central unit, according to the Times of India.

“Security measures are essential to not only address the issue of logistics and safety but also build confidence in people that the supply chain is intact, unbroken and safe to the point of delivery,” Preeti Kumar, a public health specialist, told AFP.

India gave nod for emergency use of two vaccines, one developed by Oxford University and UK-based drugmaker AstraZeneca, and another by Indian company Bharat Biotech, on January 4. Cargo planes flew 16.5 million shots to different Indian cities last week.

India has ordered an initial 11 million doses of Covishield, AstraZeneca’s vaccine made by India’s Serum Institute, at 200 rupees ($2.74) each, and 5.5 million doses of Covaxin at 206 rupees each.

The government’s “emergency approval” of Covaxin, made by India’s Bharat Biotech, has some doctors worried because Phase 3 human trials are yet to be completed.